未登录

E

Ellison Suthoff

Vertex Pharmaceuticals

H指数:13

被引数:747

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials

通过SF-36评估zuranolone对成年MDD和PPD患者的功能和幸福感的治疗益处的大小和可持续性: 对4项随机临床试验的综合分析

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2024-04-015

OAAI

The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)

美国重度抑郁症患者的经济负担 (2019)

ADVANCES IN THERAPY

IF4

2023-07-3146

OAAI

The impact of early remission on disease trajectory and patient outcomes in major depression disorder (MDD): A targeted literature review and microsimulation modeling approach based on the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2023-03-012

OAAI

Humanistic and economic burden associated with depression in the United States: a cross-sectional survey analysis

美国与抑郁症相关的人文和经济负担: 一项横断面调查分析

IF3.6

2022-08-1121

OAAI

Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2022-07-0118

PRE

Exploring the rapidity of treatment effect for current treatment options for major depressive disorder

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2021-12-010

PRE

Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2021-04-0117

OAAI

Effect of zuranolone on depression and anxiety outcomes in postpartum depression in a randomized, placebo-controlled trial

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2020-11-010

PREAI

Phase 3, randomized, placebo-controlled trial of SAGE-217 in postpartum depression: Association between HAM-D and PHQ-9

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

IF8.4

2020-01-011

OAAI

Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis

JOURNAL OF PEDIATRICS

IF3.5

2019-12-0116

PREAI

Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis

JOURNAL OF CYSTIC FIBROSIS

IF6

2019-09-0130

OAAI

Patient-Reported Health-Related Quality of Life Correlates Inversely With Depressive Symptoms in a Pivotal Trial of SAGE-217 in Major Depressive Disorder

在SAGE-217治疗重度抑郁症的关键试验中，患者报告的健康相关生活质量与抑郁症状成反比

BIOLOGICAL PSYCHIATRY

IF9

2019-05-010

PREAI

Health-related quality of life in a Phase 2, randomized, placebo-controlled trial of the GABA(A)R modulator SAGE-217 in major depressive disorder

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2019-01-010

PREAI

PATIENT REPORTED MEASURES OF DEPRESSIVE SYMPTOMS AND FATIGUE IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER

VALUE IN HEALTH

IF6

2018-10-011

OAAI

ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE BY THE SF36V2 IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER

VALUE IN HEALTH

IF6

2018-10-010

OAAI

MODELED SURVIVAL GAINS OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGED ≥12 YEARS HOMOZYGOUS FOR THE F508DEL MUTATION TREATED WITH THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR (CFTRM) TEZACAFTOR/IVACAFTOR (TEZ/IVA)

VALUE IN HEALTH

IF6

2018-05-010

PREAI

RATE OF LUNG FUNCTION DECLINE IN PATIENTS WITH CYSTIC FIBROSIS (CF) HAVING A RESIDUAL FUNCTION GENE MUTATION

IF7.7

2017-11-151

OAAI

THE CYSTIC FIBROSIS IMPACT QUESTIONNAIRE (CF-IQ): QUALITATIVE DEVELOPMENT AND COGNITIVE EVALUATION OF A NEW PATIENT-REPORTED OUTCOME INSTRUMENT TO ASSESS THE LIFE IMPACTS OF CYSTIC FIBROSIS

VALUE IN HEALTH

IF6

2017-10-010

OAAI

MEASURING GENERIC HEALTH-RELATED QUALITY OF LIFE AND IMPACT OF HEALTH RESOURCE UTILIZATION IN ADULTS WITH CYSTIC FIBROSIS

VALUE IN HEALTH

IF6

2015-11-012

PREAI

Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial

HEALTH AND QUALITY OF LIFE OUTCOMES

IF3.4

2015-07-0230

OAAI